Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
AHA 24 Late-Breaking Discussion: The FLOW Trial
Author(s): Harriette Van Spall , Added: 5 months ago
AHA Conference 2024 — Semaglutide shows increased benefits in CKD patients based on their cardiovascular status and risk profile.Dr Harriette Van Spall (McMaster University, CA) sits down with Dr Katherine Tuttle (University of Washington, US) to discuss the effects of semaglutide in patients with chronic kidney disease (CKD).The FLOW trial (NCT03819153) is designed to assess the effect of… View more

Prevention & Chronic Conditions

Cardiovascular Renal Metabolic
FLOW: Kidney, Cardiovascular, Mortality, Metabolic and Safety Results
Author(s): Richard Pratley Added: 8 months ago
EASD 24 - We are joined by Dr Richard Pratley (AdventHealth Diabetes Institute, US) to discuss the kidney, cardiovascular, metabolic, mortality and safety results from the FLOW trial.Interview Questions:1. What is the reasoning behind the FLOW Trial?2. What was the patient population and study design?3. What are the key results?4. Were there any surprising or unexpected findings?5. What further… View more

Prevention & Chronic Conditions

Cardiovascular Renal Metabolic
ADA 24: FLOW Trial: Kidney Outcomes in Patients Treated with Semaglutide
Author(s): Vlado Perkovic Added: 10 months ago
ADA 24 - In this succinct video, we are joined by Dr Vlado Perkovic (UNSW Sydney, Kensington, AU) to discuss a trial investigating the use of semaglutide in patients with type 2 diabetes and chronic kidney disease (NCT03819153).The FLOW trial enrolled 3533 participants with type 2 diabetes and chronic kidney disease, who were then randomized to recieve either semaglutide or placebo. The median… View more

Prevention & Chronic Conditions

Cardiovascular Renal Metabolic
THT 24: The ALT FLOW Early Feasibility Study
Author(s): Firas Zahr Added: 1 year ago
THT 24 - We are joined by Dr Firas Zahr (OHSU Knight Cardiovascular Institute Cardiology Clinic, US) to discuss the findings from the ALT FLOW Early Feasibility study (NCT03523416).The ALT FLOW Early Feasibility study aims to assess the initial clinical safety, functionality and effectiveness of a transcatheter atrial shunt system created by Edwards. 75 patients with symptomatic heart failure… View more

Heart Failure

Intervention
Carolyn M Webb
Research Area(s) / Expertise:
Personal History Dr Carolyn Webb is based in London, where she works as a research fellow at the National Heart and Lung Institute. Academic History Carolyn studied physiology as an undergraduate at the University of Otago, New Zealand. Then she went on to obtain her PhD in education at Imperial College London. Career Overview Carolyn Webb is a research fellow at the… View more
Yield and Characterisation of CFT in ANOCA
Author(s): Johanna McChord , Astrid Hubert , Udo Sechtem , et al Added: 6 months ago

Prevention & Chronic Conditions
ACC 25 Late-Breaking Discussion: The STRIDE Trial
Author(s): Harriette Van Spall , Marc P Bonaca Added: 1 month ago
ACC 25 - STRIDE shows subcutaneous semaglutide improved walking ability and related quality of life in patients with both type 2 diabetes and peripheral arterial disease (PAD) with intermittent claudication symptoms.Late-Breaker host, Dr Harriette Van Spall (McMaster University, Hamilton, CA) is joined by Dr Marc Bonaca (University of Colorado School of Medicine, Aurora, CO, US) to discuss the… View more

Vascular Disease and Surgery

Prevention & Chronic Conditions
ACC 25: The Phase 3 REVERSE-IT Trial
Author(s): Deepak L Bhatt Added: 1 month ago
ACC 2025 - Phase three results of the use of bentracimab in patients who need urgent ticagrelor reversal show significantly restored platelet function as measured by percent inhibition of P2Y12 Reaction Unit (PRU).Dr Deepak L Bhatt (Mount Sinai Fuster Heart Hospital, New York, US) joins us onsite at ACC 2025 to discuss phase three results from the multi-center, open-label, single-arm REVERSE-IT… View more

Anticoagulation
Echo-stress in Myocardial Bridge
Author(s): Priscilla Lamendola , Nello Cambise , Antonio Di Renzo , et al Added: 10 months ago

Prevention & Chronic Conditions
ACC 25 Late-Breaking Discussion: The FRESH-UP Trial
Author(s): Harriette Van Spall , Roland RJ van Kimmenade Added: 1 month ago
ACC 25 - FRESH-UP shows liberal fluid intake did not result in a significant difference in health status compared to fluid restriction of 1500ml per day, but did result in a lower perceived thirst distress.Dr Harriette Van Spall (McMaster University, CA) sits down with Dr Roland Van Kimmenade (Radboud University Medical Center, Nijmegen, NL) to discuss the findings from the multi-center,… View more

Heart Failure